Myelin oligodendrocyte glycoprotein-specific T-cell receptor complex (MOG-specific TCR)

The Myelin oligodendrocyte glycoprotein-specific T-cell receptor complex is a multi-subunit protein assembly located on the surface of T lymphocytes that specifically recognizes and binds to MOG peptides presented by Major Histocompatibility Complex (MHC) molecules (Bronge et al., 2022, Nature Communications). MOG is a key autoantigen located on the outermost surface of the myelin sheath in the central nervous system, making it a primary target for the autoimmune attack observed in conditions such as Multiple Sclerosis (MS) and MOG antibody-associated disease (MOGAD) (Peschl et al., 2017, Frontiers in Immunology). When this TCR complex is activated by MOG peptides, it triggers a signaling cascade that leads to T-cell proliferation, cytokine production, and the subsequent recruitment of other immune cells to the brain and spinal cord, resulting in demyelination and axonal damage. Because of its central role in driving neuroinflammation, the MOG-specific TCR complex is a high-priority target for antigen-specific immunotherapies. These therapies, including tolerogenic vaccines like ANK-700 and nanoparticle-based delivery systems like TPM203, aim to selectively silence or reprogram MOG-reactive T cells to restore immune tolerance (Anokion, 2024; Topas Therapeutics, 2022). By targeting only the autoreactive T-cell population, these approaches seek to treat the underlying cause of demyelinating diseases while avoiding the broad immunosuppression associated with conventional treatments.

Other names

MOG-reactive T-cell receptorMOG-specific TCR complexMyelin oligodendrocyte glycoprotein-reactive TCRAnti-MOG T-cell receptor

Induction of antigen-specific immune tolerance through the presentation of MOG peptides in a non-inflammatory context, leading to T-cell anergy, deletion, or conversion to regulatory phenotypes.